FDA Approves Real-Time Release NDAs As Agency, Early Adopters Promote PAT
This article was originally published in The Gold Sheet
Executive Summary
Real-time release has arrived with FDA approval of two NDAs that rely on process analytical technology instead of end-product testing for release to market. Merck shares its experience with PAT-based real-time release at IFPAC meeting, while FDA officials express disappointment that pharmaceutical industry has not embraced PAT more broadly. Research funding, agenda explored. Business case made. Sterility concerns raised. Legacy opportunities explored
You may also be interested in...
Regulators Encourage Transition from Batch to Continuous Processing
As pharmaceutical manufacturers increasingly look to continuous processing technologies as a way of controlling costs and potentially increasing drug quality, regulators in the U.S. and the European Union are beginning to use more flexible, quality-by-design-like approaches in evaluating these systems.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”